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Abstract 
Previous studies have identified many biomarkers that are associated with aging and related 
outcomes, but the relevance of these markers for underlying processes and their relationship 
to hypothesized systemic dysregulation is not clear. We address this gap by presenting a novel 
method for measuring dysregulation via the joint distribution of multiple biomarkers and 
assessing associations of dysregulation with age and mortality. Using longitudinal data from 
the Women’s Health and Aging Study, we selected a 14-marker subset from 63 blood 
measures: those that diverged from the baseline population mean with age. For the 14 markers 
and all combinatorial sub-subsets we calculated a multivariate distance called the 
Mahalanobis distance (MHBD)
2
 for all observations, indicating how “strange” each 
individual’s biomarker profile was relative to the baseline population mean.  In most models, 
MHBD correlated positively with age, MHBD increased within individuals over time, and 
higher MHBD predicted higher risk of subsequent mortality. Predictive power increased as 
more variables were incorporated into the calculation of MHBD. Biomarkers from multiple 
systems were implicated. These results support hypotheses of simultaneous dysregulation in 
multiple systems and confirm the need for longitudinal, multivariate approaches to 
understanding biomarkers in aging.  
 
Keywords: Dysregulation, biomarker, multivariate, aging, physiology
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 Abbreviations: Mahalanobis distance (MHBD), Multivariate Distance (MD), Women’s 
Health and Aging Study (WHAS), blood urea nitrogen (BUN), dehydroepiandrosterone-
sulfate (DHEA-S), high-density lipoprotein (HDL). 
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1. Introduction 
1.1 General introduction 
Epidemiological studies of aging have long used biomarkers both as a potential way to 
understand underlying processes in aging and as a way to predict patient outcomes (Crimmins 
et al. 2008; Glei et al. 2007; Martin-Ruiz et al. 2011; Walston 2005; Walston et al. 2006). 
Most such studies have used single markers, or have used composite indices based on 
relatively simple accumulation criteria (e.g., number of criteria met). However, the individual 
markers measured are almost always integrated in complex physiological regulatory networks 
involved in maintaining organismal homeostasis: this is why they are chosen. In such 
complex dynamic systems, the interpretation of the level of any one marker generally depends 
on the levels of many other markers (Cohen et al. 2012).  
Many studies now invoke physiological dysregulation (or related concepts such as 
allostatic load or homeostenosis) as a primary factor in aging (Crimmins et al. 2003; 
Gruenewald et al. 2009; Karlamangla et al. 2002; McEwen and Wingfield 2003), a hypothesis 
that appears capable of explaining the multiple mechanistic theories of aging (Medvedev 
1990) and the diversity of lifespans and aging patterns observed across species (Finch 1990). 
Under this scenario, aging is largely a system-level property caused by regulatory breakdown, 
not any lone biological mechanism such as an up-regulated gene or oxidative stress (Cohen et 
al. 2012). Multiple studies have shown associations between summary indices of allostatic 
load and aging outcomes (Crimmins et al. 2003; Glei et al. 2007; Seeman et al. 2001; Szanton 
et al. 2009).  A small number of studies have applied sophisticated statistical approaches to 
measurement of the relationships among biomarkers in the context of dysregulation, generally 
with confirmatory but complex results (Arbeev et al. 2011; Gruenewald et al. 2009; 
Karlamangla et al. 2002; Seplaki et al. 2006; Yashin et al. 2007). However, one of the major 
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challenges for the field remains the operationalization of multi-system dysregulation and 
allostatic load (Singer et al. 2004).  
Here, we present a novel approach for measuring multi-system physiological 
dysregulation. This method uses the joint distribution of multiple biomarkers to assign 
individuals a score indicating how normal or abnormal their overall profile is relative to a 
reference population. The joint distribution permits incorporation of the likelihood of 
different combinations of biomarker levels and allows for abnormal biomarker levels to be 
either high or low. Such a score has many potential uses in studies of aging: 1) Under a 
hypothesis of dysregulation, scores are expected to increase with age. Moreover, simultaneous 
dysregulation in multiple systems should result in a stronger association between multivariate 
distance and age or health outcomes as the number of variables used to compute the distance 
increases. This can be tested. 2) The contrast between the performance of scores incorporating 
different number of biomarkers can indicate the complexity of the system and whether the 
effects of biomarkers are independent from each other. 3) The performance of models 
incorporating different sets of biomarkers can be used to test hypotheses about which 
physiological systems are implicated in dysregulation and the degree to which their 
dysregulation is independent. 4) Long-term, such scores are promising as clinical tools for 
measuring degree and type of dysregulation in patients. We demonstrate the first three 
applications, showing apparent dysregulation in biomarkers from multiple physiological 
systems. Longitudinal data allow us to show both changes within individuals over time and 
higher risk of mortality among those with abnormal biomarker profiles.  
 
1.2 Specific approach 
Multivariate probability distributions can be used to calculate the probability of observing 
various combinations of variables. Conceptually this is different from using several univariate 
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distributions together – for example, although it is not particularly rare for a person to have a 
height of 190 cm or a weight of 45 kg, the combination is quite rare. Statistical distance, when 
applied to multivariate probability distributions, is a measure of how rare a certain 
combination of variables is relative to a reference population (the multivariate mean – the 
mean of all variables – has a statistical distance of 0). Additionally, most physiological 
systems are regulated to maintain parameters within a certain range, and there is often 
potential for abnormal values to occur in both directions (e.g. Seplaki et al. 2005). 
Multivariate statistical distance makes no assumptions about direction of change in different 
markers, and can integrate changes of all markers in both directions into a single analysis. We 
refer generally to analyses using multivariate statistical distance as Multivariate Distance 
(MD) analysis.  
Specifically, we use 63 biomarkers from a longitudinal cohort of elderly women, the 
Women’s Health and Aging Study. We use a measure of multivariate statistical distance, the 
Mahalanobis distance (MHBD) (De Maesschalck et al. 2000; Mahalanobis 1936), to assign 
each observation of each individual a score for distance from the baseline population mean 
(assumed to indicate “normal” physiological state) as measured simultaneously for many 
variables. We hypothesized that a “strange” overall biomarker profile, i.e. one with high 
MHBD, would be indicative of physiological dysregulation, and that this would be apparent 
as increases in MHBD with age and associations between MHBD and mortality risk. Further, 
we predicted that models including more variables in MHBD would yield better predictions. 
We demonstrate the approach on a subset of biomarkers chosen using statistical criteria; 
future studies could use biological or alternative statistical criteria. 
 
2. Methods 
2.1 Data 
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We used data from 429 women aged 70-93 in the Women’s Health and Aging Study 
(WHAS) II. This study has been described in detail elsewhere (Fried et al. 1995; Guralnik et 
al. 1995). Briefly, WHAS is a population-based, prospective study of community-dwelling 
women with no more than minimal physical disability. Participants were drawn from eastern 
Baltimore City and Baltimore County, Maryland between
 
March 1, 1994 and May 1, 1995 
(Fried et al. 2000). All women gave their informed consent prior to their inclusion in the 
study. Of
 
1630 women screened, 880 were eligible, and
 
430 agreed to participate in WHAS II 
and had a baseline examination with biomarkers measured. Eligible non-participants were less 
educated, had lower incomes, and had lower self-rated health compared to WHAS II 
participants. Follow-ups were conducted roughly 1.5, 3, 6, 7.5, and 9 years later. On average, 
the time between the first and the last recorded visits for women with at least two visits (390/429) was 
8.4 years. Each examination consisted of a comprehensive medical history, medication 
inventory, physical and neurological examination, neuropsychological battery, and blood 
draw (Fried et al. 2000). For mortality, 172 participants (40%) died during the course of the 
study, with data available through July 23, 2010 and a mean follow-up of 10.7 years.  
Blood samples were collected at seven time points, but not all collected samples have been 
analyzed for all parameters, and most have not been analyzed beyond the fourth time point. 
Sixty-three biomarkers were selected for analysis based on sufficient longitudinal sampling 
and co-occurrence in samples with other biomarkers of interest. Depending on the specific 
markers in any given analysis, there are 2-4 effective data collection points – always the 
minimum number for any included variable. Markers were mostly blood metabolites and 
included hormones, inflammatory markers, basic blood count measures, micronutrient levels, 
lipid levels, and ion levels. A full list is provided in Table 1. 
 
2.2 Analysis 
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2.2.1 Variable groupings 
Simultaneous MD analysis of all 63 biomarker variables is not feasible because: (a) the 
different patterns of age-related changes across markers may cancel each other out in 
aggregate; and (b) the assumption of multivariate normality, necessary for our methods, 
becomes untenably constraining at higher dimensions. There are many potential ways to 
choose subsets of variables for analysis, including methods that use both biological and 
statistical criteria. Our goal was not to identify the best or only groups of interest, but rather to 
choose relevant and interesting groups with which to demonstrate MD analysis. In particular, 
because we were interested in dysregulation, we used statistical criteria to choose variables 
that either increased or decreased in variability with age. 
Change in variability with age was measured using the deviance of each observation for 
each variable – the absolute value of its difference from the variable’s population mean.  This 
approach is similar to that taken previously by Seplaki et al. (2005). In order to approximate 
as much as possible a younger, healthier population, population mean was calculated based 
solely on the first visits of patients. Deviances were calculated after appropriate log- or 
square-root-transformations for normality; this preserves the sensitivity of the deviances to 
aberrant values in both directions, regardless of the original scale of the variable. 
For each variable, we then pooled deviances for all patients at all time points and assessed 
the Pearson correlation with age. Of the 63 variables included in the analyses, 14 showed 
significant (p<0.05) correlations with age and 5 showed significant negative correlations. We 
call these the positive and negative suites, respectively. These suites serve as the basis for all 
subsequent analyses. Thus, the statistical criterion selected biomarkers showing an increasing 
or decreasing average deviation from the baseline population with age. This could be due to a 
simple linear increase or decrease in average biomarker values with age, without a 
concomitant increase in total variance, or to an increase in total variance (with more extreme 
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positive and/or negative values), with or without a linear trend in average values (see Figure 
S1 for examples). The positive suite may represent variables experiencing a loss of regulatory 
control with age, and the negative suite may represent variables experiencing a loss of 
capacity to respond to changing conditions with age. We emphasize that this variable 
screening procedure is neither meant to be exhaustive (it does not detect non-monotonic 
associations with age, for example) nor highly specific (there may be false positives for either 
statistical or biological reasons), and is but one example for how variables might be chosen. 
However, these variable groupings are sufficiently coherent and small to allow a meaningful 
demonstration of MD analysis. 
 
2.2.2 Mahalanobis distance 
Mahalanobis distance (MHBD) is a measure of multivariate statistical distance for a 
multivariate normal distribution, given by the formula: 
  (1) 
where x is a multivariate observation (a vector of simultaneously observed values for the 
variables in question, such as all the biomarker values for a given patient at a given time 
point),  is the equivalent-length vector of population means for each variable, and S is the 
population variance-covariance matrix for the variables. If all variables are uncorrelated then 
this is equivalent to scaling each biomarker by its variance and then summing the squared 
deviances for an observation:  
 
DM (x) 
(xi  i )
2
 2 (xi )i1
B

 (2) 
 
where B is the number of biomarkers and 2(xi) the variance in the i
th
 biomarker. The 
behavior of MHBD thus depends not only on the identity of the variables included in the 
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calculation but also on their covariance. For instance, BUN/creatinine ratio and total 
cholesterol show opposite trends with age (Figure S1) and are uncorrelated to each other 
(r=0.024, p=0.45, n=971). MHBD (scaled by its standard deviation, see below) calculated 
from these two variables has an average of 1.78. When we permuted the values among 
individuals to obtain the maximal correlation possible given the observed data (r=0.99), 
MHBD decreased to 1.36, namely 76% of the previous value and closer to MHBD calculated 
with either variable taken separately (respectively 1.32 and 1.20 for cholesterol and 
BUN/creatinine ratio).  
In this study, we calculated  and S based on the baseline population (all individuals at 
their first visit) rather than the full population of all measurement points. This allowed us, as 
much as possible, to compare current physiological state to a healthy reference population. 
We used standard normal transformations of the raw biomarkers (log or square-root as 
necessary, then minus the mean and divided by the standard deviation) in order to give equal 
weight to all variables in the analysis. 
Multivariate normality is generally a strong assumption, and it is particularly so for the 
case of a complex dynamic system, where the relationships between the variables are 
expected to follow particular patterns that may not be captured by the assumptions related to 
standard distributions. Nonetheless, it is a conservative assumption in that, by making it, we 
are likely to miss many patterns that would be detected if we knew the true distribution. To 
the extent that the assumption is false, we are likely to decrease the probability of generating 
significant results, so it is a good starting point. We calculated MHBD for each individual at 
each time point. This was done separately for the positive suite, the negative suite, and each 
possible subset of variables within each suite (16,383 and 31 combinations, respectively).  
Statistical properties of MHBD depend on the number of variables used to calculate it. The 
scale depends on the scales and number of the variables included. The lower bound is at zero, 
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and the distribution is usually roughly log-normal, with a peak density a bit higher than zero. 
Proportional to the scale of a given MHBD, the peak tends to shift away from zero as more 
variables are included in the calculation. To account for this distribution, MHBDs were log-
transformed when included in correlations and regressions with age, though results were not 
sensitive to using the raw MHBD (data not shown). MHBDs were not log-transformed in 
analyses of mortality because we suspected that the risks increased exponentially with 
MHBD. Because the scale of MHBD changes depending on the variables included, we 
standardized MHBD by its standard deviation, or when appropriate the log of MHBD by the 
standard deviation of log-transformed value, for use in comparisons across analyses. 
 
2.2.3 Relationship to age and mortality 
For each MHBD calculated, we assessed its correlation with age (Pearson correlation 
coefficient). Significant correlations could result from either individual or population changes. 
To measure individual changes, we calculated the slope of MHBD with age for each 
individual having at least two values of all variables used to calculate the MHBD. We then 
averaged this slope across individuals, and performed a t-test to see if it was significantly 
positive or negative.  
To analyze the relationship between MHBD and mortality, we used Cox proportional 
hazards models to assess the association between MHBD and mortality risk. Specifically, we 
controlled for the age at the first visit and used the absolute time of the follow-up to model a 
time-to-event process (i.e. until either death or censoring because visits ended).   
 
2.2.4 Effect size and variables included 
In order to assess whether inclusion of more variables tended to augment or decrease our 
ability to detect effects, we compared the effect sizes and -log10 (p-values) to the number of 
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variables included in each MHBD model. Intuitively, we might suspect that inclusion of more 
variables should augment the predictive value of a model. However, this is not necessarily 
true for MHBD, where inclusion of a variable less related to age can increase the noise and 
thus decrease the signal relative to a model with fewer variables (see also Seplaki et al. 2005). 
Moreover, in our dataset, sample size decreases as more variables are included due to missing 
data, diminishing the power of the higher-order analyses.  
Lastly, in addition to asking how the predictive value of MHBD changes as more variables 
are included, we assessed the importance of each variable for the predictive power. We used 
the results of the 16,383 and 31 positive and negative subgroup analyses in univariate 
regression models to predict how the models’ effect sizes (the dependent variable) depended 
on whether a given biomarker was included in the calculation of MHBD (dichotomous; the 
independent variable). This was repeated for the correlation, slope, and mortality analyses for 
all 21 biomarkers in the positive and negative suites. 
 
3. Results 
3.1 Variable correlations with age 
Many of the 63 variables correlated with age (Table 1). We found 14 that correlated 
positively with age, 19 that correlated negatively with age, 14 with deviances that correlated 
positively (the positive suite, Table 1), and 5 with deviances that correlated negatively (the 
negative suite, Table 1). As expected given the relatively narrow range of ages and the 
absence of young individuals in our cohort, most of the correlations were relatively weak 
(0.04 < |r| < 0.36 for significant correlations). 
 
3.2 Relationship of Mahalanobis distance to age 
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We calculated MHBD for each observation for all 16,383 combinations of the 14 variables 
in the positive suite, as well as for the 31 combinations of the 5 variables in the negative suite. 
The majority of variable combinations in the positive suite produced MHBDs positively 
correlated with age (99.4% significant at p<0.05, Fig. 1a) and having positive average slopes 
with age (99.5% signif., Fig. 1b). In both cases, the inclusion of more variables in the 
calculation of MHBD resulted in larger standardized effect sizes and more significant p-
values (Figs 1a-b). The majority of variable combinations in the negative suite produced 
MHBDs negatively correlated with age as expected (80.6% signif., Fig. 2a), but paradoxically 
having positive average intra-individual slopes with age (64.5% signif., Fig. 2b).  
 
3.3 Relationship of Mahalanobis distance to mortality 
Many variable combinations in the positive suite also produced MHBDs predictive of 
mortality (survival analyses, 67.4% signif., 99.5% of relative risks in the expected direction 
(>1), Fig. 1c). On average, model performance increased as more variables were included, but 
the best models had intermediate numbers of variables (Fig. 1c). Effect size in both cases 
shows a significant negative quadratic relationship with variable number (p<0.0001). 
Although MHBD is log-normally distributed, we did not transform it for the mortality 
analyses because the risk was hypothesized to increase exponentially with MHBD score. For 
the negative suite, only one combination of variables significantly predicted mortality. 
 
3.4 Effects of individual variables 
We used linear regression to analyze how inclusion or exclusion of each variable from the 
model affected the strength of the predictions in the models above (Table 2). As expected, 
some variables contributed more information than others. For example, inclusion of 
osteocalcin in calculating MHBD tended to strongly increase the correlation, the intra-
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individual slope, and mortality prediction. The general trend for higher-order models to 
perform better depends on which variables are included. For example, sensitivity analyses 
excluding the models with osteocalcin show a much stronger association between variable 
number and slope (Figure S2; slope trend, r=0.44 compared to r=0.26; p-value trend, r=-0.09 
compared to r=-0.25; p<0.0001 for all). 
 
4. Discussion 
4.1 General discussion 
Here we have presented a novel analytical approach for studying longitudinal changes in 
suites of biomarkers with age based on the concept of statistical distance. This distance is a 
measure of the strangeness or abnormality of an individual’s biomarker profile at a moment in 
time, relative to a reference population mean. Our analyses show that, when calculated based 
on appropriate sets of variables, this statistical distance increases with age within individuals 
and predicts subsequent mortality, providing support for the role of dysregulation in aging. 
Furthermore, predictive power for both age and mortality increase as more variables are 
included in the calculation of statistical distance.  
Concordant with studies on allostatic load and aging (Crimmins et al. 2003; Glei et al. 
2007; Gruenewald et al. 2009; Karlamangla et al. 2002; Seeman et al. 2001; Seplaki et al. 
2006; Szanton et al. 2009), several lines of evidence in this study support the hypothesis of 
dysregulation in aging and MHBD as a measure of it. First, the biomarkers selected here are 
largely not those traditionally considered biomarkers of aging and functional decline (with the 
exception of cholesterol, see Table 2). This suggests global, multi-systemic dysregulation. 
Second, MHBD in the positive suite both increases with age and predicts mortality, as 
predicted for physiological dysregulation.  
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Third, predictive power tends to increase as more variables are included in the model. 
Unlike a regression model, this would not be predicted if all variables had independent 
effects; in that case, the effect of the multivariate distance would approximate the average 
effect of all the variables used to calculate it. For example, imagine we calculate MHBD 
based on just one variable that is strongly associated with age and mortality. It performs very 
well. If we add in a second variable, uncorrelated with the first, that has only a very weak 
association with age and mortality, this performance should go down because half of the 
information on statistical distance (that provided by the second variable) is largely unrelated 
to age and mortality. Thus, an individual could have a high MHBD because of “good” values 
for several variables, “poor” values for several variables, or any mix of both. On the other 
hand, under the dysregulation hypothesis it is the joint distribution of variables (not their 
independent distributions) that signals aging; in this case, the more variables included in the 
calculation the stronger the expected aging signal. Thus, the increasing predictive power of 
models with more biomarkers provides substantial support for the hypothesis that it is the 
interactions between the variables that are critical. 
Preliminary analyses (not shown) did not detect associations of statistical distance with age 
or subsequent mortality when the distance was calculated from all available biomarkers. This 
highlights the need to choose relevant suites of variables for this type of analysis. In this 
study, we used statistical selection criteria: namely, a significant correlation between age and 
the absolute deviation of the variable from the population mean. Even after this, it was 
necessary to separate the positively and negatively correlated biomarkers. We believe that the 
positive suite represents biomarkers that increasingly escape regulatory control with age, 
whereas the negative suite represents markers that increasingly fail to respond properly to 
changing conditions (either internal or external). Future studies should examine the relevance 
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of biologically rather than statistically identified suites of variables, such as inflammatory 
markers, electrolytes, and oxygen transport markers.  
Our results support hypotheses of dysregulation in aging but do not provide definitive 
proof, as we do not show direction of causality. It is possible that other underlying processes 
cause both aging and dysregulation, or that dysregulation is a result of disease, which 
increases in frequency with age and preceding mortality. In order to further test for a causal 
role of dysregulation in aging, future studies should follow patterns of dysregulation over 
longer periods of time, with various combinations of biomarkers, and in relationship to 
specific disease processes as they progress. For example, studies should address links 
between dysregulation and frailty (Fried et al. 2001; Rockwood et al. 2005), with an eye to 
understanding if frailty is a global physiological process or a result of dysregulation in one or 
several specific systems. As part of such studies, the multivariate statistical distance approach 
presented here can be applied to both functional suites of biomarkers (inflammatory markers, 
hormones, etc.) and to statistically selected suites. In addition, future analyses should combine 
multivariate distance with other approaches such as principal components analysis, grade-of-
membership models, and structural equations modeling. For example, Arbeev et al. (2011) 
presented detailed dynamic models of biomarkers, allostatic load, and health outcomes during 
aging; statistical distance could be incorporated directly into such models as a way to 
summarize multiple markers. 
 
4.2 Limitations  
It is tempting to interpret the biological significance of the individual biomarkers identified 
in this study, as well as their interactions. Indeed, it is noteworthy that the markers come from 
many different systems. Additionally, most of the markers that emerge here as the best 
predictors of aging and mortality are not traditionally considered aging biomarkers. Blood 
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urea nitrogen, basophil counts, ion levels, and hematocrit are (to our knowledge) all novel as 
aging biomarkers and deserve specific follow-up study. In contrast, creatinine, hemoglobin, 
and bilirubin have been examined individually in other studies (Ble et al. 2005; Bulpitt et al. 
2009; Den Elzen et al. 2011). However, we caution that the effects of any one biomarker may 
be due to particularities of the WHAS data set or to random chance (given the large number 
of statistical tests performed), and we prefer to refrain from over-interpreting the specific 
biomarkers that emerged in this study.  
Our analyses were designed largely without consideration of the biological functions of the 
biomarkers we measured. This was intentional: so little is known about the long-term 
structure and function of physiological regulatory networks that incorporation of specific a 
priori biological hypotheses would likely have biased our findings and prevented us from 
detecting novel patterns. Indeed, the biomarkers we found to be the most important are not the 
ones that we would have predicted a priori, such as high-density lipoprotein (HDL) 
cholesterol, C-reactive protein, and hemoglobin A1C. Our approach is justified as an 
exploratory method, but the specific effects of individual markers will need to be confirmed 
in other studies and datasets. It will also be critical to conduct complementary analyses that 
reflect clear hypotheses based on the literature, and such analyses are currently underway.  
The analyses presented here assume a multivariate normal distribution. Multivariate 
normality, rare in general, is particularly unlikely to apply to these biomarker suites, which 
are parts of physiological regulatory networks and are thus expected to follow complex 
dynamics not readily explained by standard statistical distributions. Despite this conservative 
assumption, we were able to detect strong signals in the data. Future research will explore 
non-parametric approaches to estimating statistical distance, including kernel density 
estimation and data depth (Bouezmarni and Rombouts 2010; Liu et al. 1999; Scott 2008). 
Although we performed a large number of statistical tests, the fact that 67% of all models 
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were significant at α=0.05 (much higher than the 5% expected by chance) suggests that 
concerns about false positives and multiple testing are unwarranted.  
Lastly, our study is currently limited to a single population of elderly women in one 
American city, and thus may not be generalizable to other populations. We were not able to 
follow age changes throughout the life course, and it is possible, even likely, that different 
patterns would emerge on a similar analysis of women aged 45-70, or of men, for example.  
 
5. Conclusions 
Using a novel method for measuring multi-systemic dysregulation during aging, we have 
shown that abnormal physiological states are associated with increasing age and risk of 
mortality. The increasing performance of measures including more biomarkers shows that 
abnormal state results from the interactions among variables, not just their independent 
effects. Our results agree with previous studies on physiological dysregulation but used a 
different set of markers. This suggests that dysregulation is a generalized process that can be 
measured through many different sets of biomarkers. This is supported by the diverse 
physiological systems represented by the biomarkers in this study. Our results are consistent 
with, though not proof of, dysregulation itself as a fundamental cause of aging. Our method 
can be widely applied to similar data sets or other suites of biomarkers, and in the long run 
such comparisons will help establish the biological pathways involved in aging-associated 
dysregulation. 
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Table 1: Biomarkers analyzed and their correlations with age   
    
n 
Raw variable   
Deviance from 
baseline mean 
  
Category/system 
  r p  r p  
The positive suite         
 Red blood cell count (r) 1967 -0.03 0.24  0.09 <0.0001  Blood, circulation 
 Hemoglobin (r) 1967 -0.09 0.0001  0.07 0.002  Blood, circulation 
 Hematocrit (r) 1967 -0.02 0.28  0.06 0.006  Blood, circulation 
 Osteocalcin (l) 999 0.34 <0.0001  0.29 <0.0001  Bone metabolism 
 Calcium (r) 1990 0.05 0.02  0.09 <0.0001  Ions 
 Sodium (r) 1990 -0.02 0.32  0.14 <0.0001  Ions 
 Potassium (r) 1990 0.07 0.004  0.07 0.003  Ions 
 Chloride (r) 1990 -0.12 <0.0001  0.04 0.05  Ions 
 Total cholesterol (r) 1287 -0.17 <0.0001  0.10 0.0005  Lipids 
 BUN-creatinine ratio (r) 1991 0.36 <0.0001  0.25 <0.0001  Liver, kidney, proteins,  excretion 
 Creatinine (l) 1991 -0.13 <0.0001  0.22 <0.0001  Liver, kidney, proteins,  excretion 
 Albumin (r) 1990 -0.16 <0.0001  0.06 0.005  Liver, kidney, proteins,  excretion 
 Bilrubin (direct) (l) 1083 0.08 0.007  0.07 0.03  Liver, kidney, proteins,  excretion 
 Basophils (r) 972 -0.03 0.34  0.09 0.005  White blood cell counts 
The negative suite         
 Alanine transaminase (l) 1990 0.08 0.0003  -0.07 0.001  Liver, kidney, proteins,  excretion 
 Alkaline 22aemoglobin (l) 1989 -0.02 0.45  -0.06 0.01  Liver, kidney, proteins,  excretion 
 Vitamin D hydroxyl (r) 805 -0.04 0.25  -0.12 0.0009  Micronutrients 
 Vitamin D dihydroxyl (r) 1070 -0.02 0.49  -0.07 0.02  Micronutrients 
 Ferritin (l) 1085 -0.01 0.75  -0.07 0.02  Oxygen transport 
Other biomarkers         
 Mean corpuscular volume (r) 1967 0.01 0.68  -0.03 0.17  Blood, circulation 
 Red cell distribution width (l) 1966 0.00 0.86  -0.03 0.17  Blood, circulation 
 Platelet count (r) 1957 0.03 0.16  0.02 0.40  Blood, circulation 
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Mean corpuscular 
23aemoglobin conc. (r) 
1967 -0.16 <0.0001  -0.02 0.44  Blood, circulation 
 
Mean corpuscular haemoglobin 
(r) 
1967 -0.08 0.0004  0.01 0.64  Blood, circulation 
 Mean platelet volume (r) 875 -0.07 0.05  -0.02 0.64  Blood, circulation 
 Estradiol (l) 1286 -0.19 <0.0001  0.05 0.09  Endocrine 
 Thyroxine (r) 1093 -0.04 0.18  -0.05 0.11  Endocrine 
 IGF-1 (r) 1075 0.01 0.84  -0.05 0.13  Endocrine 
 
Thyroid stimulating hormone 
(s) 
1281 0.16 <0.0001  0.03 0.23  Endocrine 
 Parathyroid hormone (intact) (l) 984 0.02 0.54  0.02 0.47  Endocrine 
 DHEA-S (l) 1450 -0.09 0.0005  0.01 0.57  Endocrine 
 
Parathyroid hormone (serum 
mid-region) (l) 
994 0.02 0.50  0.02 0.59  Endocrine 
 Interleukin-6 (l) 1094 -0.02 0.57  0.03 0.29  Inflammation 
 C-reactive protein (l) 1078 -0.08 0.01  -0.02 0.42  Inflammation 
 Magnesium (r) 1050 0.05 0.12  0.05 0.11  Ions 
 Phosphate (r) 1084 0.01 0.75  0.00 0.87  Ions 
 Triglycerides (l) 1287 -0.10 0.0006  0.02 0.51  Lipids 
 Cholesterol-HDL ratio (l) 1084 -0.09 0.004  0.01 0.73  Lipids 
 HDL (r) 1291 0.03 0.33  0.00 0.95  Lipids 
 Aspartate aminotransferase (l) 1989 0.20 <0.0001  0.04 0.08  Liver, kidney, proteins,  excretion 
 G-glutamyl transferase (l) 1084 0.01 0.71  -0.03 0.28  Liver, kidney, proteins,  excretion 
 Lactate dehydrogenase (r) 1082 -0.03 0.31  0.03 0.34  Liver, kidney, proteins,  excretion 
 Uric acid (r) 1084 -0.07 0.02  0.03 0.40  Liver, kidney, proteins,  excretion 
 Total Protein (r) 1990 -0.09 0.0001  0.02 0.47  Liver, kidney, proteins,  excretion 
 Globulin (r) 1084 -0.07 0.02  -0.02 0.48  Liver, kidney, proteins,  excretion 
 Albumin-globulin ratio (r) 1084 0.01 0.66  -0.02 0.53  Liver, kidney, proteins,  excretion 
 Bilirubin (total) (l) 1990 -0.03 0.19  0.01 0.64  Liver, kidney, proteins,  excretion 
 Folate (l) 1085 0.18 <0.0001  -0.05 0.11  Micronutrients 
 Vitamin B12 (l) 1083 0.01 0.76  -0.04 0.20  Micronutrients 
 Vitamin A (r) 767 -0.04 0.24  0.03 0.36  Micronutrients 
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 Vitamin B6 (l) 594 0.11 0.005  -0.03 0.53  Micronutrients 
 Total iron-binding capacity (r) 1083 0.01 0.63  -0.03 0.40  Oxygen transport 
 Saturated transferring (r) 1086 0.02 0.61  0.01 0.70  Oxygen transport 
 Iron (r) 1083 0.02 0.45  0.01 0.87  Oxygen transport 
 Glycohemoglobin (l) 912 0.01 0.69  -0.06 0.08  Sugar metabolism 
 Protein-bound glucose (l) 1083 0.07 0.02  -0.04 0.17  Sugar metabolism 
 Glucose (l) 1989 -0.15 <0.0001  0.03 0.20  Sugar metabolism 
 Hemoglobin a1c (l) 1059 -0.08 0.01  -0.004 0.91  Sugar metabolism 
 White blood cell count (r) 1967 0.10 <0.0001  -0.04 0.06  White blood cell counts 
 Monocytes (r) 973 0.00 0.93  0.05 0.14  White blood cell counts 
 Eosinophils (l) 973 0.07 0.03  -0.02 0.49  White blood cell counts 
 Differential poly (r) 972 0.12 0.0001  0.00 0.91  White blood cell counts 
  Lymphocytes (r) 973 -0.15 <0.0001  0.00 0.96  White blood cell counts 
Results where p<0.05 are in bold; results where p<0.05 and the correlation is negative are in red. All variables were transformed as 
necessary for normality, coded (r) = raw, (l) = log, and (s) = square-root. All correlations were performed on data pooled across 
individuals and time points. DHEA-S indicates dehydroepiandrosterone-sulfate; HDL indicates high-density lipoprotein. 
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Table 2: Effect of inclusion of each raw variable on the predictivity of Mahalanobis distance 5 
for different models 
 Raw correlation 
 Intra-individual 
slope 
 Mortality 
relative risk  
  p   p   p 
The positive suite         
Red blood cell count 0.006 <0.0001  -0.0065 0.002  -0.0468 <0.0001 
Hemoglobin -0.0076 <0.0001  -0.0167 <0.0001  -0.0059 <0.0001 
Hematocrit -0.0009 0.5065  -0.0177 <0.0001  -0.022 <0.0001 
Osteocalcin 0.1447 <0.0001  0.2638 <0.0001  0.0919 <0.0001 
Calcium 0.0178 <0.0001  -0.0019 0.3578  0.0315 <0.0001 
Sodium 0.005 0.0001  0.0091 <0.0001  -0.0014 0.2149 
Potassium -0.0048 0.0003  0.0046 0.0275  0.0255 <0.0001 
Chloride 0.003 0.0231  -0.0017 0.4274  -0.0002 0.8727 
Total cholesterol -0.0112 <0.0001  -0.0021 0.3119  0.0205 <0.0001 
BUN-creatinine ratio 0.0068 <0.0001  0.0103 <0.0001  -0.0239 <0.0001 
Creatinine -0.0017 0.2066  0.01 <0.0001  0.0363 <0.0001 
Albumin -0.0011 0.3905  -0.0023 0.2672  -0.0022 0.052 
Bilrubin (direct) -0.0272 <0.0001  0.0127 <0.0001  0.0364 <0.0001 
Basophils -0.0062 <0.0001  0.0042 0.0482  0.024 <0.0001 
The negative suite         
Vitamin D hydroxyl -0.013 0.098  -0.004 0.804  0.056 0.009 
Alkaline phosphatase 0.001 0.889  0.048 0.001  0.048 0.026 
Vitamin D dihydroxyl -0.016 0.041  0.062 <0.0001  -0.070 0.001 
Alanine transaminase -0.007 0.389  0.003 0.865  -0.008 0.724 
Ferritin -0.026 <0.0001  -0.001 0.932  0.051 0.018 
Results of regression models predicting the effect sizes of other models based on the inclusion or exclusion of 
each biomarker in the calculation of MHBD. For example, the -coefficient of 0.006 for the raw correlation of 
MHBD with red blood cell count indicates that the r for the correlation between MHBD and age was 0.006 
higher on average if red blood cell count was one of the variables used to calculate MHBD. The second set of 
columns refers to the within-individual changes in MHBD over time, and the third to the relative risk of 
mortality based on Cox regression. The positive suite analyses are based on the 16,383 combinations of the 14 
variables includes, and the negative suite analyses on the 31 combinations of the 5 variables included. 
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Fig. 1. Changes in predictive power of MHBD with increasing numbers of variables from the 10 
positive suite used in its calculation. Each circle represents an analysis based on one of the 
16,383 combinations of the 14 variables in the positive suite. Color indicates p-value: black: 
p0.1; blue: 0.05≤p<0.1; cyan: 0.01≤p<0.05; yellow- green: 0.001≤p<0.01; orange: 
0.0001≤p<0.001; red: p<0.0001. The line represents a linear regression of number of 
variables on relevant effect size. Effect size trend shows the results of a Pearson correlation 15 
analysis of variable number with relevant effect size, and P-value trend shows the results of a 
Pearson correlation analysis of variable number with log10(p-value). (a) Correlation of MHBD 
with age; (b) mean intra-individual slope of MHBD with age; (c) relative risk based on Cox 
proportional hazards of mortality before next visit. In (b) – (c), effect sizes are standardized as 
indicated in text. 20 
 
 
Fig. 2. Changes in predictive power of MHBD with increasing numbers of variables from the 
negative suite used in its calculation. Each circle represents an analysis based on one of the 31 
combinations of the 5 variables in the negative suite. Color indicates p-value: black: p0.1; 25 
blue: 0.05≤p<0.1; cyan: 0.01≤p<0.05; yellow- green: 0.001≤p<0.01; orange: 
0.0001≤p<0.001; red: p<0.0001. The line represents a linear regression of number of 
variables on relevant effect size. Effect size trend shows the results of a Pearson correlation 
analysis of variable number with relevant effect size, and P-value trend shows the results of a 
Pearson correlation analysis of variable number with log10(p-value). (a) Correlation of MHBD 30 
with age; (b) mean intra-individual slope of MHBD with age; (c) relative risk based on Cox 
proportional hazards of mortality before next visit. In (b) – (c), effect sizes are standardized as 
indicated in text. 
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Figure S1 Trends in eight selected biomarkers with age. To be retained by our statistical selection criterion (i.e. 45 
a significant correlation between deviation from the basal “healthy” population and age) a marker could show 
different types of patterns (see Methods). For instance, osteocalcin increases with age but not its variance. As a 
result, both the raw measurement and its deviance from the basal population are positively correlated with age 
and there is no increase in extreme negative values. A mirror situation is observed for creatinine where the 
measurement is correlated negatively with age and its deviance positively. The positive correlation for the 50 
thyroid stimulating hormone is not mainly due to a steady linear increase with age but rather to the occurrence of 
more extreme negative values at intermediate ages. Thus, the deviance is not itself correlated with age. Sodium 
shows a correlation only in the deviance, with older women tending to show a greater variance (hence more 
frequent extreme values). The BUN-creatinine ratio shows an increase with age of both the raw measurement 
and the deviance. DHEAS shows a slight albeit significant decrease with age but not its deviance (no more or 55 
less extreme values at higher age, whatever positive, negative or both). Cholesterol is the mirror of osteocalcin, 
with the raw measurement correlated negatively and its deviance positively with age. Finally, for CRP both the 
measurement and the deviance show a negative correlation with age although in the latter case it is very weak 
and does not cross the significance level. Since deviance is always is relative to the variation observed at 
younger ages, i.e. at the first visit, all these markers except TSH, DHEAS and CRP were retained by our 60 
statistical criterion. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
31 
 
 
Fig. S2. Figure 1 omitting Osteocalcin. Changes 
in predictive power of MHBD with increasing 
numbers of variables from the positive suite used 65 
in its calculation. Each circle represents an 
analysis based on one of the 16,383 
combinations of the 14 variables in the positive 
suite. Color indicates p-value: black: p0.1; 
blue: 0.05≤p<0.1; cyan: 0.01≤p<0.05; yellow- 70 
green: 0.001≤p<0.01; orange: 0.0001≤p<0.001; 
red: p<0.0001. The line represents a linear 
regression of number of variables on relevant 
effect size. Effect size trend shows the results of 
a Pearson correlation analysis of variable 75 
number with relevant effect size, and P-value 
trend shows the results of a Pearson correlation 
analysis of variable number with log10(p-value). 
(a) Correlation of MHBD with age; (b) mean 
intra-individual slope of MHBD with age; (c) 80 
relative risk based on Cox proportional hazards 
of mortality before next visit. In (b) – (c), effect 
sizes are standardized as indicated in text. 
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